One‐year treatment of chronic urticaria with mizolastine: efficacy and safety

Lorette, G; Giannetti, Alberto; Pereira, RS; Leynadier, F.; Murrieta‐Aguttes, Margarita

doi:10.1046/j.1468-3083.2000.00014.x

Cited by 21 publications

(11 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several clinical studies demonstrated the efficacy of mizolastine in treating the symptoms of CIU [60,61,62,63]. In a 4-week multi-centre, double-blind, parallel-group study of 247 patients with CIU, mizolastine 10 mg/day was shown to be as effective as loratadine 10 mg/day with respect to reduction of pruritus and episodes of urticaria, compared with placebo (p < 0.009) [61].…”

Section: Chronic Idiopathic Urticariamentioning

confidence: 99%

“…Lorette et al [63] reported the long-term efficacy and safety of daily oral mizolastine (10 or 15 mg) in a 1-year open-label trial of 127 patients with CIU. After 2 months of therapy, patients receiving mizolastine experienced improvements in overall discomfort, itching, angioedema and a reduction in the number and size of wheals.…”

Section: Chronic Idiopathic Urticariamentioning

confidence: 99%

“…However, one study showed that mizolastine 15 mg/day was associated with a slight increase in AEs compared with placebo [55]. The long-term safety of mizolastine was demonstrated in patients receiving daily treatment with mizolastine (5 and 10 mg) for 6 months -1 year, where the incidence of adverse events was not significantly different from the placebo group [59,63]. The lack of ECG changes observed during one year of treatment [63] suggests that mizolastine is not cardiotoxic, although high concentrations of mizolastine have been shown to block HERG-related potassium channels.…”

Section: Safetymentioning

confidence: 99%

“…The long-term safety of mizolastine was demonstrated in patients receiving daily treatment with mizolastine (5 and 10 mg) for 6 months -1 year, where the incidence of adverse events was not significantly different from the placebo group [59,63]. The lack of ECG changes observed during one year of treatment [63] suggests that mizolastine is not cardiotoxic, although high concentrations of mizolastine have been shown to block HERG-related potassium channels. Blockade of these channels may interrupt the ventricular inward potassium rectifier current, I Kr , causing prolonged cardiac repolarisation, which can result in ventricular arrhythmias [64].…”

Section: Safetymentioning

confidence: 99%

See 3 more Smart Citations

Antihistamines in late-phase clinical development for allergic disease

Salmun

2002

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

Allergic rhinitis (AR) is a global health concern and shares a high comorbidity with asthma. Recent research suggests that different allergic diseases, such as AR, asthma, allergic conjunctivitis and chronic idiopathic urticaria (CIU), are evoked by common pathological mechanisms characterised by the release of histamine and other inflammatory mediators. Although H(1) receptor antagonists are the mainstay of therapy for allergic disease, the unacceptably high incidence of anticholinergic and CNS-related side effects of first-generation H(1) antagonists led to the search for improved second-generation H(1) antagonists. While many of these agents were largely devoid of CNS side effects, their tendency for drug-drug interactions (e.g., terfenadine and astemizole) resulted in an increased incidence of cardiotoxicity. Furthermore, second-generation H(1) antagonists exhibited weak anti-inflammatory properties and had no effect on nasal congestion. These observations emphasised the need for newer anti-allergic agents with a broader spectrum of activity and an improved safety profile. Among the newer H(1) antagonists currently in clinical development, desloratadine and mizolastine are the most widely studied. Both have a rapid onset of action, and desloratadine has demonstrated clinical efficacy in AR, CIU and seasonal asthma. Desloratadine has several advantages over other H(1) antagonists in that it has proven decongestant activity, a sparing effect on the use of bronchodilators (beta(2)-agonists) and a low potential for drug interactions. The broad anti-inflammatory properties of desloratadine and mizolastine, which distinguish these agents from other H(1) antagonists in clinical development (e.g., norastemizole and levocetirizine), suggest they may have a more profound impact on the underlying disease in patients suffering from different forms of allergy. The lack of clinical efficacy and safety data on rupatadine and HSR-609, both novel H(1) antagonists, precludes an accurate assessment of their potential for treating allergic disease. Epinastine and efletirizine are being developed exclusively for topical application and are unlikely to play a significant role in the management of allergic diseases as a whole.

show abstract

Section: Chronic Idiopathic Urticariamentioning

confidence: 99%

Section: Chronic Idiopathic Urticariamentioning

confidence: 99%

Section: Safetymentioning

confidence: 99%

Section: Safetymentioning

confidence: 99%

See 2 more Smart Citations

Antihistamines in late-phase clinical development for allergic disease

Salmun

2002

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

show abstract

“…A study aiming to assess the long-term safety of mizolastine has shown that one-year mizolastine treatment did not change the QT c intervals, and no significant changes in mean systolic and diastolic blood pressures have occurred [65]. However, concentrations of mizolastine higher than those achieved during standard therapy are able to block HERGrelated potassium channels [66].…”

Section: Mizolastinementioning

confidence: 99%

Adverse Systemic Reactions of Antihistamines: Highlights in Sedating Effects, Cardiotoxicity and Drug Interactions

Kus¹

2005

CMCAIAA

View full text Add to dashboard Cite

Antihistamines are already among the most frequently used pharmaceutical compounds and with the predictable increase of the prevalence of atopic disease, even more patients are expected to use them in future. Though the common belief on their safety has existed since some decades, they, including the over the counter ones, might potentially bear serious side effects. Thus , the following article focuses on the adverse effects of antihistamines by summarizing the current data mainly on central nervous system and cardiovascular side effects. Meanwhile, less common side effects, and important issues like their use in pregnancy and lactation are also included. Updated information is provided on drug interactions and overdose situations along with their management. As a finalstep, pitfalls in choosing suitable antihistamine/s in special circumstances to avoid adverse effects are also covered.

show abstract

Pharmacoepidemiology and drug safety

2001

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 19 sections: 1 Books, Reviews & Symposia; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

One‐year treatment of chronic urticaria with mizolastine: efficacy and safety

Abstract: Mizolastine improves CU symptoms, and these improvements are sustained over 12 months with no loss of drug sensitivity. No specific side-effects are associated with its long-term use in the current study.

Cited by 21 publications

References 29 publications

Antihistamines in late-phase clinical development for allergic disease

Antihistamines in late-phase clinical development for allergic disease

Adverse Systemic Reactions of Antihistamines: Highlights in Sedating Effects, Cardiotoxicity and Drug Interactions

Pharmacoepidemiology and drug safety

Contact Info

Product

Resources

About